Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tianjin Pharmaceutical Da Ren Tang GroupSTU:2TZ +1.67%72 Return-on-Tangible-Equity is 24.62% as of Mar. 2026, which is 92% above its 10-year median of 12.82. GuruFocus rates STU:2TZ with a GF Score™ of 72/100 and a GF Value™ of €1.64 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 900 Drug Manufacturers companies, Tianjin Pharmaceutical Da Ren Tang Group ranks better than 85.89% on this metric.
STU:2TZ'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.95 Med: 12.82 Max: 32.55
Current: 27.96
During the past 13 years, Tianjin Pharmaceutical Da Ren Tang Group's highest Return-on-Tangible-Equity was 32.55%. The lowest was 10.95%. And the median was 12.82%.
STU:2TZ's Return-on-Tangible-Equity is ranked better than 85.89% of 900
companies
in the Drug Manufacturers industry
Industry Median: 7.925
vs STU:2TZ: 27.96
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Tianjin Pharmaceutical Da Ren Tang Group Return-on-Tangible-Equity Related Terms
Tianjin Pharmaceutical Da Ren Tang Group Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group Return-on-Tangible-Equity Chart
Tianjin Pharmaceutical Da Ren Tang Group Annual Data
STU:2TZ vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 24.62% mean?
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) has a Return-on-Tangible-Equity of 24.62% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. This is 92% above median its historical median of 12.82. Over the past decade, Tianjin Pharmaceutical Da Ren Tang Group's Return-on-Tangible-Equity has ranged from 10.95 to 32.55. According to the industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #127 out of 900 companies in the Drug Manufacturers industry, placing it in the top 14.1%.
Is Tianjin Pharmaceutical Da Ren Tang Group's Return-on-Tangible-Equity too high?
Tianjin Pharmaceutical Da Ren Tang Group's current Return-on-Tangible-Equity of 24.62% is 92% above median its 10-year median of 12.82. Over the past 10 years, this metric has ranged from a low of 10.95 to a high of 32.55. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.93. Tianjin Pharmaceutical Da Ren Tang Group's value of 24.62% is 210.7% above this industry median. Based on the distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #127 out of 900 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #127 out of 900 companies for Return-on-Tangible-Equity. This places Tianjin Pharmaceutical Da Ren Tang Group in the top 14% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.93. Tianjin Pharmaceutical Da Ren Tang Group's value of 24.62% is 210.7% above this benchmark. Historically, Tianjin Pharmaceutical Da Ren Tang Group's own Return-on-Tangible-Equity has ranged from 10.95 to 32.55 over the past decade. While the company's 10-year median is 12.82 vs. the industry median of 7.93, Tianjin Pharmaceutical Da Ren Tang Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.93, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin Pharmaceutical Da Ren Tang Group's current Return-on-Tangible-Equity of 24.62% is 210.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin Pharmaceutical Da Ren Tang Group's current Return-on-Tangible-Equity is 24.62%, which is 92% above median its own 10-year median of 12.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.64, compared to a current price of €2.44 — trading 48.8% above its estimated fair value. The current Return-on-Tangible-Equity is 24.62%, which is 92% above median its 10-year median of 12.82 and 210.7% above the Drug Manufacturers industry median of 7.93. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ), the current Return-on-Tangible-Equity is 24.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued.
The current stock price of €2.44 is trading 48.8% above its estimated GF Value™ of €1.64.
GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.
Key valuation signals for STU:2TZ:
Return-on-Tangible-Equity: 24.62% (92% above median its 10-year median of 12.82)
GF Value™: €1.64 vs. price of €2.44 (48.8% above fair value)
Industry Position: 210.7% above the Drug Manufacturers median (#127 of 900)
No single metric tells the full story. See the STU:2TZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin Pharmaceutical Da Ren Tang Group Business Description
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
72GF Score
Get the complete analysis for STU:2TZ
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2TZ has been successfully added to your 
